Chemical Industry Snapshot

www.jubl.com. "The new website provides responsive interface, modern design

aesthetics and easy navigation for visitor experience," informed a company press

statement. Commented on the launch, Ms. Nidhi Malik, Head-Marketing &

Communications, Jubilant Life Sciences said, "Our fully revamped corporate

website acts as a unifying point of contact across businesses, subsidiaries and

functions. The navigation in the new website has been made simpler and now

visitors will have an easy and a quick access to important information, such as our

product portfolio, data pertaining to investor interests, sustainability initiatives,

current openings and many more." At the revamped website, visitors can on one

click receive content on R&D activities, post product queries, learn about

innovation in drug discovery, and access information on Jubilant Group, stocks,

quarterly results and more.

Eli Lilly targets slot in top-20 in India by 2020

Eli Lilly and Co. is looking to introduce more innovation-based products across five

therapeutic segments, including diabetes, over the next six years as it aims to

become one of the top 20 pharmaceutical companies in the country. The company,

which recently launched an insulin delivery pen ‘ ‘Humapen Savvio’ ‘ currently

holds around 47th position in terms of revenues among pharma companies in

FRPT Research 18
 Chemical Industry Snapshot

India. "We are committed to India and it is our aim to be among the top twenty

pharma companies in India by 2020," said Eli Lilly and Co. India Managing

Director, Mr. Edgard A. Olaizola. The company lays maximum emphasis on its

diabetes portfolio and would be introducing new products to cater to over 60-mn

patients in the country, he added. Besides, the company has presence in

osteoporosis, cardiovascular, oncology and growth hormones segments. "Although

diabetes remains our largest vertical, we would also be focusing on other areas,

including oncology," he said. As part of enhancing its diabetes product portfolio,

the company launched the insulin delivery pen, which the company plans to

provide free to physicians. It will be available in pharmacies for Rs. 1,000 per

piece. The pen, which can be used for six years to deliver insulin, will be co-

promoted by Lilly-Boehringer Ingelheim alliance in India.

Biocon to take breast cancer drug to emerging markets

Bangalore-based biotechnology company, Biocon Ltd. is planning to take its

recently launched breast cancer drug to other emerging markets. ‘CANMAb’, jointly

developed with US-based Mylan Inc, will be launched in Latin America, West Asia

and North Africa, where breast cancer cases are on the rise. "We have to get

regulatory approvals, but are keen to get into those markets," Chairman and

FRPT Research 19
Copyright of FRPT- Chemical Snapshot is the property of FRPT Research and its content
may not be copied or emailed to multiple sites or posted to a listserv without the copyright
holder's express written permission. However, users may print, download, or email articles for
individual use.